Addex Therapeutics' GABAB PAM Candidate Shows Potential For Alcohol Use Disorder

  • Addex Therapeutics (NASDAQ: ADXN) has announced that a review published in Alcohol and Alcoholism suggests that positive allosteric modulators (PAMs) of the gamma-aminobutyric acid B (GABAB) receptor could potentially offer a new treatment option for patients with severe alcohol use disorder.
  • Though GABAB receptor agonists, such as baclofen, have been shown to reduce addiction-related behaviors in preclinical studies. However, the therapeutic use of baclofen is minimal due to significant side-effects, including sedation, drowsiness, and sleepiness.
  • Addex's GABAB PAM, ADX71441, demonstrated efficacy on several alcohol-related behaviors in rat models and potently decreased binge-like drinking, reduced relapse-like drinking, and dose-dependently reduced alcohol self-administration as well as lowering motivation to consume alcohol.
  • Clinical studies are expected to start in 2022.
  • Price Action: ADXN stock increased 4.1% at $11.99 in market trading hours on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsGeneralalcohol addiction
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!